Zacks Research Has Pessimistic View of Novavax Q4 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at Zacks Research cut their Q4 2026 earnings per share estimates for Novavax in a research report issued to clients and investors on Wednesday, February 26th. Zacks Research analyst S. Ganoria now expects that the biopharmaceutical company will earn $0.40 per share for the quarter, down from their prior forecast of $0.45. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Several other analysts also recently commented on NVAX. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. BTIG Research initiated coverage on Novavax in a research report on Friday. They issued a “buy” rating and a $19.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $18.00.

Novavax Price Performance

NVAX opened at $8.33 on Friday. The firm has a market capitalization of $1.33 billion, a PE ratio of -3.69, a P/E/G ratio of 2.85 and a beta of 2.14. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86. The company’s 50-day moving average is $8.52 and its 200 day moving average is $10.00.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the previous year, the company posted ($1.44) EPS.

Hedge Funds Weigh In On Novavax

A number of large investors have recently made changes to their positions in the stock. E Fund Management Co. Ltd. lifted its holdings in Novavax by 5.1% during the 4th quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 1,219 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,598 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Novavax by 0.4% in the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 1,664 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Novavax by 12.0% in the third quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 2,072 shares during the period. Finally, Federated Hermes Inc. grew its stake in Novavax by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 50,506 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 2,124 shares in the last quarter. 53.04% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director James F. Young sold 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the sale, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. This represents a 9.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now owns 14,770 shares of the company’s stock, valued at $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,150 shares of company stock valued at $119,641. 1.00% of the stock is owned by insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.